关于先锋

Company Profile

Company profile

R & D innovation

Cooperation profile

R&d innovation

R&d innovation

Anhui Pioneer Pharmaceutical Co., Ltd. was established in January 2004. Since the establishment of the company, it has attached great importance to project development. The company's R&D center covers an area of 1,000 square meters and has established a R&D management system. Anhui Pioneer Pharmaceutical Co., Ltd. has been rated as "National High-tech Enterprise", "Gazelle Enterprise" and "High-precision Special New Enterprise".

The company's R&D center has more than 30 full-time R&D personnel, including 3 doctors and 6 masters. The products developed mainly cover four major therapeutic areas: hypertension, hyperlipidemia, spirit, respiratory and digestion, and general health.

Since 2020, there are 7 clinical record varieties; 14 varieties have been declared; 4 drug approval documents have passed the consistency evaluation or deemed consistency evaluation, among which fenofibrate capsule (specification: 0.2g) is the first to pass the variety; There are more than 40 varieties under development, and the declarations mainly involve antibiotics, psychotropic drugs, general health drugs, and antiviral drugs.

Complying with national policies and promoting the development of the pharmaceutical industry, the company has developed into a technology-led production-oriented enterprise. The company has deployed the consistency evaluation work of all approval documents, which has come to an end. From 2023, the company will launch high-end generic drugs to lay a solid foundation for the future development of the company. Base.

Attached is a list of Anhui Pioneer's recent R&D projects

Serial number Project name Indication Classification Estimated time to market
1 Lamotrigine Dispersible Tablets Spiritual 2024
2 minoxidil liniment General health category 2024
3 Levofloxacin Injection Antibiotics 2024
4 Cefotaxime Sodium for Injection Antibiotics 2024
5 Cefuroxime Sodium for Injection Antibiotics 2024
6 Cefazolin Sodium for Injection Antibiotics 2024
7 Ceftriaxone Sodium for Injection Antibiotics 2024
8 Cefoxitin Sodium for Injection Antibiotics 2024
9 Sildenafil Citrate Orally Disintegrating Tablets General health category 2025
10 Orlistat Capsules General health category 2025
11 Lacosamide injection Spiritual 2025
12 Vardenafil Hydrochloride Tablets General health category 2025
13 Biapenem for Injection Antibiotics 2025
14 Ertapenem for injection Antibiotics 2025
15 Diltiazem hydrochloride for injection First Aid 2025
16 Glucosamine Sulfate Capsules General health category 2024

公司简介

安徽省先锋制药有限公司是一家集生产、销售、科研于一体的综合型国家高新技术企业，企业成立于2004年1月，注册资本2000万元，位于国家级高新区的中心地带，占地30余亩，建筑面积30000㎡。企业建有国内先进的冻干粉针剂、头孢粉针剂、胶囊剂、片剂、颗粒剂、外用溶液剂、中药提取等多条生产线，产品覆盖心血管、呼吸、抗菌消炎等多个治疗领域。

公司拥有职工300余人，本科及以上学历占比达40%；技术中心专职研发人员38人，执业药师8人；企业自成立以来，累计纳税近3亿元，企业勇于承担社会责任，解决本地就业问题，为本地税收做出较大贡献。公司先后通过“国家级高新技术企业”、“合肥市亩均贡献A类企业”、“安徽省专精特新中小企业”、“高新区瞪羚企业”、“安徽省企业技术中心”“合肥市工程研究中心（合肥市新盐型药物工程研究中心）”、“安徽省三重一创高新技术企业增长补助”、“合肥市三重一创高新技术企业增长补助”、“合肥高新区三重一创补助”、“合肥市企业技术中心”、“深科技企业”、“安徽省皖美品牌企业”等荣誉认证。

2015年公司在上海张江高科建立了现代化的研究所上海皓锋医药科技有限公司，依托张江国家开发区的地域及资源优势，为公司源源不断的注入新的活力。公司整合上海皓锋研发基地和合肥总部研发中心资源，建立了安徽省企业技术中心，构建了较为完善的以企业为主体，产、学、研、用相结合的技术创新体系，与安徽中医药大学、上海交通大学、安徽省农业大学等高校开展多种形式研发合作。

在全国医药市场结构调整的大环境下，我公司不断加强研发力量、创新营销模式、探索市场开拓新渠道，公司进入了一种良性的发展轨道。公司产品也建立了良好市场口碑，公司主导产品注射用盐酸克林霉素、注射用克林霉素磷酸酯、归脾胶囊和甘草酸二铵肠溶片等被市场所认可，市场覆盖全国近30个省份。其中皓瑞®注射用盐酸克林霉素、百思宁®归脾胶囊自2018年以来，连续5年占同类产品市场份额排名第一。

2023年安徽省先锋制药正式启动上市计划，计划2026年企业在北交所和创业板上市挂牌，企业第一个五年计划结束后，将迎来企业展翅腾飞、焕发新生的美好未来！